Tee, K.B.; Ibrahim, L.; Hashim, N.M.; Saiman, M.Z.; Zakaria, Z.H.; Huri, H.Z.
Pharmacokinetic–Pharmacometabolomic Approach in Early-Phase Clinical Trials: A Way Forward for Targeted Therapy in Type 2 Diabetes. Pharmaceutics 2022, 14, 1268.
https://doi.org/10.3390/pharmaceutics14061268
AMA Style
Tee KB, Ibrahim L, Hashim NM, Saiman MZ, Zakaria ZH, Huri HZ.
Pharmacokinetic–Pharmacometabolomic Approach in Early-Phase Clinical Trials: A Way Forward for Targeted Therapy in Type 2 Diabetes. Pharmaceutics. 2022; 14(6):1268.
https://doi.org/10.3390/pharmaceutics14061268
Chicago/Turabian Style
Tee, Khim Boon, Luqman Ibrahim, Najihah Mohd Hashim, Mohd Zuwairi Saiman, Zaril Harza Zakaria, and Hasniza Zaman Huri.
2022. "Pharmacokinetic–Pharmacometabolomic Approach in Early-Phase Clinical Trials: A Way Forward for Targeted Therapy in Type 2 Diabetes" Pharmaceutics 14, no. 6: 1268.
https://doi.org/10.3390/pharmaceutics14061268
APA Style
Tee, K. B., Ibrahim, L., Hashim, N. M., Saiman, M. Z., Zakaria, Z. H., & Huri, H. Z.
(2022). Pharmacokinetic–Pharmacometabolomic Approach in Early-Phase Clinical Trials: A Way Forward for Targeted Therapy in Type 2 Diabetes. Pharmaceutics, 14(6), 1268.
https://doi.org/10.3390/pharmaceutics14061268